BiotechTube

Zoster Vaccine, Live

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Herpes Zoster

Conditions

Herpes Zoster, Varicella-zoster Vaccine

Trial Timeline

Apr 1, 2011 → May 1, 2015

NCT ID
NCT01245751

About Zoster Vaccine, Live

Zoster Vaccine, Live is a phase 3 stage product being developed by Merck for Herpes Zoster. The current trial status is completed. This product is registered under clinical trial identifier NCT01245751. Target conditions include Herpes Zoster, Varicella-zoster Vaccine.

What happened to similar drugs?

5 of 20 similar drugs in Herpes Zoster were approved

Approved (5) Terminated (1) Active (14)
🔄V212 + PlaceboMerckPhase 3
🔄zoster vaccine live (ZOSTAVAX™) + Comparator: PlaceboMerckPhase 3
🔄ZOSTAVAXMerckPhase 3
🔄Zoster Vaccine, Live (AMP) + Zoster Vaccine, LiveMerckPhase 3
🔄V212 + Matching placeboMerckPhase 3
❌V212 Lot 1 + V212 Lot 2 + V212 Lot 3MerckPhase 3
🔄Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ + Comparator: placebo (concomitant-vaccine matched) + Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23MerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01245751Phase 3Completed

Competing Products

20 competing products in Herpes Zoster

See all competitors
ProductCompanyStageHype Score
mRNA-1608ModernaPhase 2
0
mRNA-1468ModernaPhase 2
0
ASP2151 + Valacyclovir hydrochlorideAstellas PharmaPhase 2
35
ASP2151 + PlaceboAstellas PharmaPhase 1
29
ASP2151 + valacyclovir + PlaceboAstellas PharmaPhase 2
35
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
GSK1349572 + EfavirenzShionogiPhase 1
29
Zoster Vaccine, Live + Comparator: PlaceboMerckPhase 2
35
Comparator: V212 + Comparator: PlaceboMerckPhase 1
29
V212 + PlaceboMerckPhase 3
40
zoster vaccine live (ZOSTAVAX™) + Comparator: PlaceboMerckPhase 3
40
ZOSTAVAXMerckPhase 3
40
Zoster Vaccine, Live (AMP) + Zoster Vaccine, LiveMerckPhase 3
40
V212 + PlaceboMerckPhase 2
35
V212 + Matching placeboMerckPhase 3
40
V212 Lot 1 + V212 Lot 2 + V212 Lot 3MerckPhase 3
32
HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9%MerckPhase 1
21
V212 + PlaceboMerckPhase 1
29
Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ + Comparator: placebo (concomitant-vaccine matched) + Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23MerckPhase 3
40
ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal + ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal + Full Dose Intradermal Placebo + Intradermal PlaceboMerckPhase 1
29